Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis-results from two randomized controlled trials.

Arthritis Res Ther · 2023 · PMC10463764 · PMID 37626399

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

After 12 weeks of treatment in the DANISH study, the biomarker levels showed a numerical trend to be lower or equal in BASDAI50 responders vs non-responders, in patients with ASDAS ≥ CII, ASDAS CII, or ASDAS MI vs ASDAS NI, respectively.

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.